Company profile
Metagenomi, Inc. Common Stock
NASDAQ: MGX · Healthcare · Biotechnology
PublicHQ Emeryville, CIK 0001785279Reports USD
#525 of 1,417 Healthcare companies by revenuebottom-quartile growth
EA Score
40DFH 45DQ 27GM —SS 66
v0.1 · 55/100 weight · provisional
↑ listing tenure, balance-sheet leverage · ↓ disclosure history, revenue growth (YoY)
Methodology →Revenue TTM
$13.6M
Rev growth YoY (TTM)
-59.8%
Net income (FY)
-$87.9M
Employees
118
as of 2026-08-19
Market cap
$45.6M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$25.2M$25.2M2025
Net income-$87.9M-$87.9M2025
Operating income-$96.0M-$96.0M2025
Total assets$221.1M$221.1M2025
Liabilities$62.5M$62.5M2025
Equity$158.6M$158.6M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Metagenomi, Inc. Common Stock’s revenue?
Metagenomi, Inc. Common Stock booked $25.2M in FY2025 revenue, contracting 52% year over year — slower than 82% of Healthcare companies we track, at a -348.5% net margin.
Peers · Healthcare
Gelesis Holdings, Inc.——Avant Brands Inc.59CEntrada Therapeutics, Inc.46DIonic Brands Corp.——Halo Collective Inc.——Precipio, Inc.69BKey facts
CEOJian Irish
SectorHealthcare
IndustryBiotechnology
HeadquartersEmeryville, null
ExchangeNASDAQ: MGX
Employees118
IPO date2006-04-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.